Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges

(2014) Siwen Hu-Lieskovan et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation

(2014) T. Bald et al.   Cancer Discovery

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

(2014) Z. A. Cooper et al.   Cancer Immunology Research

BRAF-targeted therapy alters the functions of intratumoral CD4+T cells to inhibit melanoma progression

(2014) Ping-Chih Ho et al.   OncoImmunology

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

(2013) Deborah A. Knight et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression

(2013) Georgina V. Long et al.   Pigment Cell & Melanoma Research

Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells

(2013) Bishu Sapkota et al.   OncoImmunology

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

(2013) Zachary A. Cooper et al.   OncoImmunology

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

(2012) I. Verbrugge et al.   CANCER RESEARCH

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

(2012) Richard C. Koya et al.   CANCER RESEARCH

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

(2012) C. Liu et al.   CLINICAL CANCER RESEARCH

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression

(2012) William L. Redmond et al.   PLoS One

The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

(2012) Asís Palazón et al.   Cancer Discovery

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

(2012) Anna Hooijkaas et al.   OncoImmunology

BRAF inhibition improves tumor recognition by the immune system

(2012) Marco Donia et al.   OncoImmunology

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

(2011) B. B. Aggarwal et al.   BLOOD

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Myeloid-derived suppressor cell heterogeneity and subset definition

(2010) Elisa Peranzoni et al.   CURRENT OPINION IN IMMUNOLOGY

Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

(2010) K. Takeda et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity

(2008) Y. H. Kim et al.   CANCER RESEARCH

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells

(2008) Ilaria Marigo et al.   IMMUNOLOGICAL REVIEWS

Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice

(2008) Seong-A Ju et al.   INTERNATIONAL JOURNAL OF CANCER